Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Gastroesophageal reflux disease (GERD) is arguably the most common chronic gastrointestinal disorder, characterized by symptoms of heartburn and regurgitation. The primary objectives of GERD treatment are to provide symptom relief, heal erosive esophagitis, and prevent future complications. Available treatment options for GERD are limited; over-the-counter (OTC) antacids are frequently used for acute symptom relief, while proton pump inhibitors (PPIs) have remained the mainstay of chronic therapy, along with lifestyle modifications. However, there is growing concern regarding the side effects associated with long-term use of PPIs, and the number of patients who are nonresponsive to PPIs is increasing, leading to possible shifts in the treatment approach. This report provides insights into current patient-level drug-prescribing patterns among newly diagnosed and recently treated GERD patients.
Longitudinal patient-level claims data analysis
Key drugs covered
Proton pump inhibitors, histamine H2-receptor antagonists, antacids, and gastroprokinetic agents
Key analysis provided
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Already a Client? Log in to access this report.
Matthew Scutcher is Therapy Leader for the Immune & Inflammatory research team at DRG. In this role, he leads a team of 13 Research Associates, Business Insights Analysts and Directors responsible for analyzing some of the largest and most dynamic markets in the pharmaceutical industry He has been with DRG since 2009 and holds a from University College London and a Master’s degree in Chemical Engineering from Imperial College London.
Ritesh Gupta is a Lead Analyst on the immune and inflammatory disorders team at Decision Resources Group, whose work focuses primarily on Psoriatic Arthritis, Ulcerative Colitis and Crohn’s Disease. He holds a degree in Cell Biology from Max Delbrück Center for Molecular Medicine, Berlin, where he worked on development of novel inhibitors for HGF/MET signaling pathways. Prior to joining DRG, Ritesh has worked as an assistant manager with BioXcel corporation and provided insights on various consulting projects. He was also associated with GVK Biosciences and worked on drug repurposing projects.